These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 27672308)

  • 1. Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis.
    Cohan S
    Biologics; 2016; 10():119-38. PubMed ID: 27672308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Daclizumab: A Review in Relapsing Multiple Sclerosis.
    Shirley M
    Drugs; 2017 Mar; 77(4):447-458. PubMed ID: 28211007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic drug evaluation of daclizumab for the treatment of relapsing-remitting multiple sclerosis.
    Patti F; Chisari CG; D'Amico E; Zappia M
    Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):341-352. PubMed ID: 29363337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daclizumab: Development, Clinical Trials, and Practical Aspects of Use in Multiple Sclerosis.
    Baldassari LE; Rose JW
    Neurotherapeutics; 2017 Oct; 14(4):842-858. PubMed ID: 28707278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and safety of daclizumab and its potential role in the treatment of multiple sclerosis.
    Milo R
    Ther Adv Neurol Disord; 2014 Jan; 7(1):7-21. PubMed ID: 24409199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Daclizumab high-yield process in the treatment of relapsing-remitting multiple sclerosis.
    Preiningerova JL; Vachova M
    Ther Adv Neurol Disord; 2017 Jan; 10(1):67-75. PubMed ID: 28450896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spotlight on daclizumab: its potential in the treatment of multiple sclerosis.
    Milo R; Stüve O
    Degener Neurol Neuromuscul Dis; 2016; 6():95-109. PubMed ID: 30050372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daclizumab and its use in multiple sclerosis treatment.
    Milo R; Osherov M
    Drugs Today (Barc); 2017 Jan; 53(1):7-18. PubMed ID: 28387383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daclizumab (anti-CD25) in multiple sclerosis.
    Pfender N; Martin R
    Exp Neurol; 2014 Dec; 262 Pt A():44-51. PubMed ID: 24768797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis.
    Rose JW; Giovannoni G; Wiendl H; Gold R; Havrdová E; Kappos L; Selmaj KW; Zhao J; Riester K; Tsao LC; Greenberg SJ
    Mult Scler Relat Disord; 2017 Oct; 17():32-40. PubMed ID: 29055471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daclizumab in multiple sclerosis.
    Perez-Miralles FC
    Rev Neurol; 2018 Apr; 66(8):271-282. PubMed ID: 29645071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daclizumab for relapsing remitting multiple sclerosis.
    Liu J; Wang LN; Zhan S; Xia Y
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008127. PubMed ID: 24363032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
    Wynn D; Kaufman M; Montalban X; Vollmer T; Simon J; Elkins J; O'Neill G; Neyer L; Sheridan J; Wang C; Fong A; Rose JW;
    Lancet Neurol; 2010 Apr; 9(4):381-90. PubMed ID: 20163990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.
    Bielekova B; Howard T; Packer AN; Richert N; Blevins G; Ohayon J; Waldmann TA; McFarland HF; Martin R
    Arch Neurol; 2009 Apr; 66(4):483-9. PubMed ID: 19364933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
    Kappos L; Wiendl H; Selmaj K; Arnold DL; Havrdova E; Boyko A; Kaufman M; Rose J; Greenberg S; Sweetser M; Riester K; O'Neill G; Elkins J
    N Engl J Med; 2015 Oct; 373(15):1418-28. PubMed ID: 26444729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population PK-PD analyses of CD25 occupancy, CD56
    Diao L; Hang Y; Othman AA; Mehta D; Amaravadi L; Nestorov I; Tran JQ
    Br J Clin Pharmacol; 2016 Nov; 82(5):1333-1342. PubMed ID: 27333593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daclizumab for the treatment of adults with relapsing forms of multiple sclerosis.
    Osherov M; Milo R
    Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1037-1047. PubMed ID: 28803486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.
    Gold R; Giovannoni G; Selmaj K; Havrdova E; Montalban X; Radue EW; Stefoski D; Robinson R; Riester K; Rana J; Elkins J; O'Neill G;
    Lancet; 2013 Jun; 381(9884):2167-75. PubMed ID: 23562009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis.
    Krueger JG; Kircik L; Hougeir F; Friedman A; You X; Lucas N; Greenberg SJ; Sweetser M; Castro-Borrero W; McCroskery P; Elkins J
    Adv Ther; 2016 Jul; 33(7):1231-45. PubMed ID: 27251051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of IL-2Rα with daclizumab for treatment of multiple sclerosis.
    Wiendl H; Gross CC
    Nat Rev Neurol; 2013 Jul; 9(7):394-404. PubMed ID: 23732529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.